Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Oct 15;166(8):894-901.
doi: 10.1093/aje/kwm157. Epub 2007 Jul 26.

Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk

Affiliations

Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk

Shelley S Tworoger et al. Am J Epidemiol. .

Abstract

Although oral contraceptives are protective for ovarian cancer, it is unclear how long this protection persists. The authors prospectively assessed this question as well as associations of other, less studied contraceptive methods (tubal ligation, rhythm method, diaphragm, condoms, intrauterine device, foam, spousal vasectomy) and infertility with ovarian cancer risk among 107,900 participants in the US Nurses' Health Study. During 28 years of follow-up (1976-2004), 612 cases of invasive epithelial ovarian cancer were confirmed. Duration of oral contraceptive use was inversely associated with risk (p-trend = 0.02), but no clear trend was observed for years since last use. However, for women using oral contraceptives for >5 years, the rate ratio for ovarian cancer for <or=20 years since last use was 0.58 (95% confidence interval (CI): 0.39, 0.87), with no association found for >20 years since last use (rate ratio (RR) = 0.92, 95% CI: 0.61, 1.39). Tubal ligation (RR = 0.66, 95% CI: 0.50, 0.87) was associated with decreased ovarian cancer risk, whereas intrauterine device use (RR = 1.76, 95% CI: 1.08, 2.85) and infertility (RR = 1.36, 95% CI: 1.07, 1.75) were associated with an increased risk. Results suggest that the beneficial effect of oral contraceptives on ovarian cancer risk attenuates after 20 years since last use. Furthermore, tubal ligation, intrauterine device use, and infertility were associated with ovarian cancer risk.

PubMed Disclaimer

Similar articles

Cited by

  • Non-contraceptive benefits of oral hormonal contraceptives.
    Schindler AE. Schindler AE. Int J Endocrinol Metab. 2013 Winter;11(1):41-7. doi: 10.5812/ijem.4158. Epub 2012 Dec 21. Int J Endocrinol Metab. 2013. PMID: 23853619 Free PMC article.
  • Association of Combined Estrogen-Progestogen and Progestogen-Only Contraceptives with the Development of Cancer.
    Williams WV, Mitchell LA, Carlson SK, Raviele KM. Williams WV, et al. Linacre Q. 2018 Nov;85(4):412-452. doi: 10.1177/0024363918811637. Epub 2019 Jan 3. Linacre Q. 2018. PMID: 32431377 Free PMC article. Review.
  • Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers.
    Qian F, Rookus MA, Leslie G, Risch HA, Greene MH, Aalfs CM, Adank MA, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K, Andrulis IL, Arnold N, Arun BK, Ausems MGEM, Azzollini J, Barrowdale D, Barwell J, Benitez J, Białkowska K, Bonadona V, Borde J, Borg A, Bradbury AR, Brunet J, Buys SS, Caldés T, Caligo MA, Campbell I, Carter J, Chiquette J, Chung WK, Claes KBM, Collée JM, Collonge-Rame MA, Couch FJ, Daly MB, Delnatte C, Diez O, Domchek SM, Dorfling CM, Eason J, Easton DF, Eeles R, Engel C, Evans DG, Faivre L, Feliubadaló L, Foretova L, Friedman E, Frost D, Ganz PA, Garber J, Garcia-Barberan V, Gehrig A, Glendon G, Godwin AK, Gómez Garcia EB, Hamann U, Hauke J, Hopper JL, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Jakubowska A, Janavicius R, John EM, Karlan BY, Kets CM, Laitman Y, Lázaro C, Leroux D, Lester J, Lesueur F, Loud JT, Lubiński J, Łukomska A, McGuffog L, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Miller A, Montagna M, Mooij TM, Mouret-Fourme E, Nathanson KL, Nehoray B, Neuhausen SL, Nevanlinna H, Nielsen FC, Offit K, Olah E, Ong KR, Oosterwijk JC, Ottini L, Parsons MT, Peterlongo P, Pfeiler G, Pradhan N, Radice P, Ramus SJ, Rantala J, Rennert G, Robson M, Rodriguez GC, S… See abstract for full author list ➔ Qian F, et al. Br J Cancer. 2019 Jul;121(2):180-192. doi: 10.1038/s41416-019-0492-8. Epub 2019 Jun 19. Br J Cancer. 2019. PMID: 31213659 Free PMC article.
  • The detection, treatment, and biology of epithelial ovarian cancer.
    Gubbels JA, Claussen N, Kapur AK, Connor JP, Patankar MS. Gubbels JA, et al. J Ovarian Res. 2010 Mar 29;3:8. doi: 10.1186/1757-2215-3-8. J Ovarian Res. 2010. PMID: 20350313 Free PMC article.
  • Use of fertility drugs and risk of ovarian cancer.
    Diergaarde B, Kurta ML. Diergaarde B, et al. Curr Opin Obstet Gynecol. 2014 Jun;26(3):125-9. doi: 10.1097/GCO.0000000000000060. Curr Opin Obstet Gynecol. 2014. PMID: 24752005 Free PMC article. Review.

Publication types

MeSH terms

Substances